Stem cell pioneer sets sights on Japan – Japan Times features Neil Riordan, PhD of Medistem Panama

Japan Times Article Medistem

“We enjoy the advantage of having a large amount of clinical data on 2,000 patients. So we analyzed who received which cells and which cells worked best in different conditions. This allowed us to create our selection process through molecular profiling,” explained Medistem (Panama) Founder and CEO Dr. Neil Riordan.

Operating what is arguably the country’s most advanced laboratory, an 8,000-sq-ft facility in the City of Knowledge science and technology cluster, Medistem has raised its profile in recent years as it develops stem cell-based products for clinical trials for treatment of autism, asthma, multiple sclerosis, osteoarthritis, rheumatoid arthritis and spinal cord injuries.

Utilizing its patented technologies, Medistem harvests human adult stem cells from umbilical cords, tissues and blood as well as from bone marrow and adipose tissue. “We have intellectual property on a methodology for basically defining which are good cells, which are mediocre and which are the useless ones. The U.S. Food and Drug Administration has approved our cells for compassionate use in the United States. This is a big step,” Riordan said.

Compassionate use, also known as expanded access, refers to the use of investigational new drugs outside of a clinical trial by patients with serious, life-threatening conditions. After finishing its first prospective clinical trial, and with six others in the pipeline, the company is considering the favorable regulatory conditions for cell therapy in Japan, now a promising market for its products.

“Japan has a law on the books that allows a company of our size to commercialize such products. That makes it our number one priority. We are gearing up to present our data to regulators, as well holding talks with potential partners over there,” Riordan added.

US FDA Green Lights Second Duchenne’s Muscular Dystrophy Patient To Receive Human Umbilical Cord Stem Cells In US

(PRWEB) MAY 26, 2016

Cell Dividing in SuspensionAfter several promising treatments in Panama using stem cell technology developed by Medistem Panama Inc. at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his first umbilical cord tissue-derived mesenchymal stem cells in the US earlier this year following FDA approval of a second application for a single patient, investigational new drug (IND) for compassionate use.

Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.

This trial marks the second time the FDA has granted an investigational allogeneic stem cell IND for Duchenne’s in the United States.

Ryan Benton, the first DMD patient to be treated in the US with umbilical cord stem cells just celebrated his 30th birthday, a landmark age for any Duchenne’s patient. The FDA recently approved a request to increase Ryan’s treatments from two to three times per year. Since his treatments began in September 2014, Ryan’s condition has stabilized and there have not been any adverse side effects reported.

The new subject had traveled to the Stem Cell Institute in Panama several times for treatments similar to Ryan’s. Encouraging results and news of Ryan’s compassionate use trial prompted his parents to seek out a similar trial for him in the US, which was recently granted by the FDA.

Since 2007, The Stem Cell Institute has treated patients with human umbilical cord tissue-derived mesenchymal stem cells for autism, cerebral palsy, heart failure, multiple sclerosis, osteoarthritis, rheumatoid arthritis and spinal cord injury.

In Panama, the institute is currently providing clinical services for Translational Biosciences’ Institutional Review Board-approved phase 1/2 clinical trials for autism, MS, osteoarthritis, rheumatoid arthritis and spinal cord injury. It anticipates approvals for cerebral palsy and heart failure trials in the future. For more information about see: Translational Biosciences on ClinicalTrials.gov.

Renowned stem cell scientist Neil H. Riordan, PhD, developed the stem cell technology being utilized in this trial. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama, and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for this trial.

The Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for researching unmet medical needs, is providing financial assistance for this trial.

About Stem Cell Institute Panama

Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells and donor human umbilical cord stem cells to treat: autism, cerebral palsy, multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for autism, multiple sclerosis, osteoarthritis, rheumatoid arthritis, and spinal cord injury using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) and hU-MSC-derived mesenchymal trophic factors (MTF). In the future, Translation Biosciences expects to expand its clinical trial portfolio to include heart disease and cerebral palsy.

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.

Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Website: http://www.medistempanama.com

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama
Phone: +507 306-2601
Fax: +507 306-2601

About Translational Biosciences

A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences Web Site: http://www.translationalbiosciences.com

First Duchenne’s Muscular Dystrophy Patient To Receive Umbilical Cord Stem Cell Therapy In US Turns 30

The first patient with Duchenne Muscular Dystrophy to be granted FDA approval for allogeneic adult stem cell therapy in the United States turned 30 this year, well surpassing his original life expectancy and paving the way for future patients, according to non-profit organization Coming Together For A Cure.

Duchenne Muscular Dystrophy Patient and Stem Cell Recipient, Ryan Benton

Ryan Benton

WICHITA, KANSAS (PRWEB) MAY 18, 2016 – Ryan Benton was diagnosed with Duchenne Muscular Dystrophy (DMD) at the age of three and given a life expectancy in the late teens to early twenties. DMD is a relatively common progressive genetic disorder, which causes aggressive deterioration of the muscles.

In 2009, at the age of 22, Benton’s condition was critical. He met with the founder of the Stem Cell Institute in Panama City, Panama and Medistem Panama, Neil H. Riordan, PhD. Research had shown that adult stem cell therapy might have the potential to reverse the progression of DMD.

Because of the laws restricting adult stem cell therapy in the United States, Benton was forced to travel to Panama to receive his first life-saving treatment. Ryan made seven trips to Panama to receive treatments from Dr. Riordan’s team of physicians at the Stem Cell Institute.

“Ryan has seen vast improvements in muscle mass and lung capacity as a result of his treatments…”

Ryan was assured at the start that there was no guarantee that we would find success but we knew it was his only hope in fighting the disease, especially since his health was at a critical point. Ryan could tell shortly after the first treatment that something was working. He found a renewed strength that he had never felt before and not once did he see any adverse side effects. He trusted Dr. Riordan and felt safe and eager to undergo additional treatments.

It took five years of hard work and successful treatments, but Benton became the first (and only) DMD patient granted FDA approval for this form of medical therapy inside the United States. An investigational new drug (IND) for compassionate use application was approved, allowing Benton to receive treatment in his hometown, Wichita, KS.

Approval from the FDA came with many stipulations, however. This form of treatment was to be used for only a single patient, twice a year for 3 years.

By all accounts, January 2016 was a major milestone. The FDA has recently granted an additional treatment per year, now allowing Ryan three total treatments per year, as well as approval for a second compassionate use IND for another patient. This second patient, a six-year-old boy, has also shown success from previous treatments in Panama. He received his first treatment in the United States this year .

Ryan and his family have been actively involved in the local muscular dystrophy community, and have personally known dozens of others with DMD who have passed away at far too young of an age. That number continues to grow each day, which only continues to frustrate Ryan and his family as they fight for this treatment to be more readily available for others suffering from the same disease. Ryan believes that if treated early enough, patients could have a strong chance to live a “normal” life. Ryan believes if he had been treated when he was six years old, it could be very likely that he would never have faced any of the diseases debilitating effects.

Ryan has seen vast improvements in muscle mass and lung capacity as a result of his treatments, but we believe additional treatments on a more frequent basis would help ensure maximum potential when it comes to reversing the progression of his disease. Immediately following each round of treatment, we see dramatic increases in his overall health, stamina, physical strength, and ease in ability to breathe. Unfortunately, we have found that on average, three to four months after each treatment, the effectiveness of the cells begins to decrease. We believe the FDA’s permission to increase the number of treatments per year will help safeguard Ryan’s ability to preserve his improvements and more effectively control his Duchenne’s Muscular Dystrophy. Video: Ryan Benton discusses stem cell therapy for DMD
For many families that have lived alongside, or suffered from this disease, this is very exciting news. Ryan and his family are continually heart stricken as they hear of another member of their md community has died far too young due to the disease. It’s their hope they can help provide other families the same opportunities that they were so fortunate to receive.

Coming Together for a Cure, (CTFAC) is a non-profit organization founded by Benton’s siblings, Lauren and Blake after Ryan’s first round of treatments in 2009. In the 7 years since the Bentons were given new hope, they’ve been hard at work raising awareness and support for adult stem cell research and therapy.

To find more information about their organization, their family, or to find out how you can help, please visit http://www.comingtogetherforacure.org

For all other inquiries, please email comingtogetherforacure(at)gmail(dot)com

Modulation of Cytokines in Cancer Patients by Intravenous Ascorbate Therapy

IV-Vitamin-CNina Mikirova, Neil Riordan, Joseph Casciari

Med Sci Monit 2016; 22:14-25
DOI: 10.12659/MSM.895368

BACKGROUND: Cytokines play an important role in tumor angiogenesis and inflammation. There is evidence in the literature that high doses of ascorbate can reduce inflammatory cytokine levels in cancer patients. The objective of this study was to investigate the effect of treatment by intravenous vitamin C (IVC) on cytokines and tumor markers.

MATERIAL AND METHODS: With the availability of protein array kits allowing assessment of many cytokines in a single sample, we measured 174 cytokines and additional 54 proteins and tumor markers in 12 cancer patients before and after a series of IVC treatments.

RESULTS: Presented results show for our 12 patients the effect of treatment resulted in normalization of many cytokine levels. Cytokines that were most consistently elevated prior to treatments included M-CSF-R, Leptin, EGF, FGF-6, TNF-α, β, TARC, MCP-1,4, MIP, IL-4, 10, IL-4, and TGF-β. Cytokine levels tended to decrease during the course of treatment. These include mitogens (EGF, Fit-3 ligand, HGF, IGF-1, IL-21R) and chemo-attractants (CTAC, Eotaxin, E-selectin, Lymphotactin, MIP-1, MCP-1, TARC, SDF-1), as well as inflammation and angiogenesis factors (FGF-6, IL-1β, TGF-1).

CONCLUSIONS: We are able to show that average z-scores for several inflammatory and angiogenesis promoting cytokines are positive, indicating that they are higher than averages for healthy controls, and that their levels decreased over the course of treatment. In addition, serum concentrations of tumor markers decreased during the time period of IVC treatment and there were reductions in cMyc and Ras, 2 proteins implicated in being upregulated in cancer.

Read Full Article…

Why Stem Cells Work: Clinical Trials for Spinal Cord Injury, Multiple Sclerosis, Rheumatoid Arthritis, and Duchenne’s Muscular Dystrophy

Neil Riordan, PhD speaks at the Riordan-McKenna Institute and Stem Cell Institute fall seminar in Southlake, Texas on October 10, 2015.

Dr. Riordan discusses:

  • How our lab selects uses specialized screening techniques to select only the stem cells that we know will be the most useful for our patients. Only about 1 in 100 cords pass this screening process.
  • How umbilical cord mesenchymal stem cells (MSC) control inflammation, modulate the immune system and stimulate regeneration.
  • How the number and function of our own stem cells decline over time.
  • How MSC secretions promote healing
  • Where MSCs are found in our body
  • First clinic trial in the US using umbilical cord tissue-derived stem cells
  • How MSC doubling times dramatically decrease as people age, which is why cord cells are much more robust than a patient’s own cells as they age
  • The origin of Medistem Lab in Panama
  • Why the Stem Cell Institute and Medistem Labs are in Panama
  • Stem cell therapy laws and approvals around the world
  • Global interest in mesenchymal stem cell therapy research
  • Current clinical trials using mesenchymal stem cells
  • Clinical trials in Panama
  • Collaborations with corporations and educational institutions
  • Mesenchymal stem cell selection, donor selection, and testing
  • Brief tour of Medistem Panama stem cell laboratory
  • Isolation and production of mesenchymal stem cells
  • Discovery of mesenchymal stem cells in menstrual blood
  • Umbilical cord mesenchymal stem cell studies for rheumatoid arthritis
  • The role of T-regulatory cells in rheumatoid arthritis and multiple sclerosis
  • Treating spinal cord injuries with mesenchymal stem cells
  • Mechanism of mesenchymal stem cells on spinal cord injury. They are not becoming tissue. It’s their secretions that allow the spinal cord to heal itself.
  • Umbilical cord MSC studies on spinal cord injury
  • Data from Stem Cell Institute spinal cord injury patients
  • Video from treated spinal cord injury patients
  • Postnatal MSC safety
  • MSCs and cancer risk – MSCs have been shows to actually inhibit tumor growth

Stem Cell-Augmented Achilles Tendon Rupture Repair Yields Excellent Results

Int Orthop. 2015 May;39(5):901-5. doi: 10.1007/s00264-015-2725-7. Epub 2015 Mar 22.

Outcomes of acute Achilles tendon rupture repair with bone marrow aspirate concentrate (BMAC) augmentation

Stein BE, Stroh DA, Schon LC.

“Excellent results, including no re-ruptures and early mobilisation, were observed…”

Abstract

Kobe-AchillesPURPOSE:
Optimal treatment of acute Achilles tendon ruptures remains controversial. Positive results using stem-cell-bearing concentrates have been reported with other soft-tissue repairs, but no studies exist on outcomes of bone marrow aspirate concentrate (BMAC) augmentation in primary Achilles tendon repair.

METHODS:
We reviewed patients with sport-related Achilles tendon ruptures treated via open repair augmented with BMAC injection from 2009 to 2011. Data on operative complications, strength, range of motion, rerupture, calf circumference and functional improvement through progressive return to sport and the Achilles tendon Total Rupture Score (ATRS) were analysed.

RESULTS:
A total of 27 patients (28 tendons) treated with open repair and BMAC injection were identified (mean age 38.3 ± 9.6 years). At mean follow-up of 29.7 ± 6.1 months, there were no reruptures. Walking without a boot was at 1.8 ± 0.7 months, participation in light activity was at 3.4 ± 1.8 months and 92% (25 of 27) of patients returned to their sport at 5.9 ± 1.8 months. Mean ATRS at final follow-up was 91 (range 72-100) points. One case of superficial wound dehiscence healed with local wound care. No soft-tissue masses, bone formation or tumors were observed in the operative extremity.

CONCLUSIONS:
Excellent results, including no re-ruptures and early mobilisation, were observed in this small cohort with open Achilles tendon repair augmented by BMAC. No adverse outcomes of biologic treatment were observed with this protocol. The efficacy of BMAC in the operative repair of acute Achilles tendon ruptures warrants further study.

LEVEL OF EVIDENCE:
IV – Therapeutic.

Ruptured Achilles Tendon Treatment at Dr. Riordan’s Clinic in Dallas-Fort Worth

At Riordan-McKenna Institute, Dr. McKenna performs a procedure for achilles tendon rupture that is similar to the one described in this study. However, Dr. McKenna augments the BMAC injection with AlphaGEMS amniotic tissue product. AlphaGEMS is a pliable tissue allograft (transplant) derived from human placental amnion, which contains over 100 growth factors and functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. The inclusion of AlphaGEMS adds a new dimension to the tissue repair process.

For more information about BMAC and AlphaGEMS treatment at RMI, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

If you have suffered a ruptured achilles tendon and would like to be evaluated for treatment at RMI, the first step is to complete an online medical history. Once we receive it, our staff will contact you to answer general questions and to guide you through the rest of the evaluation process, which usually requires recent MRI images and an MRI report.

https://secureform.rmiclinic.com/forms/13299/3207/VVp7/form.html

Study on Compensated Rotator Cuff Tear Arthropathy by Orthopedic Surgeon and Stem Cell Specialist, Wade McKenna, DO Published in Techniques in Shoulder and Elbow Surgery

Dallas-Fort Worth, Texas (PRWEB) November 08, 2015

A Study by orthopedic surgeon and stem cell specialist, Dr. Wade McKenna of the Riordan-McKenna Institute entitled, “Outpatient Treatment of Compensated Cuff Arthropathy Using Inlay Arthroplasty With Subscapularis Preservation” is published in the December edition of Techniques in Shoulder and Elbow Surgery.

Picture of Dr. Wade McKenna

Dr. McKenna

Dr. McKenna is co-founder and chief medical officer of the Riordan-McKenna Institute of Regenerative Orthopedics (RMI) in Southlake, Texas. Co-author of this work is Troy Chandler, PA-C from North Central Texas Orthopedics in Decatur, Texas.

Rotator cuff tear arthropathy sometimes develops in patients who have had a very large, long-standing rotator cuff injury. In CTA, changes in the shoulder due to the rotator cuff tear cause arthritis and lead to destruction of joint cartilage.

The Shoulder HemiCAP® restoration procedure is designed to match the shape and contour of individual patient’s cartilage and joint surface and be an ideal alternative to shoulder replacement. It simply recreates a smooth surface where the cartilage has worn away — similar to a filling for a tooth cavity.

The study examined a consecutive series of 50 CTA patients treated by Dr. McKenna from 2007 to 2015. It concluded that resurfacing the humeral head (shoulder bone) using a HemiCAP shoulder implant preserves the joint and avoids bone loss and complications associated with more invasive procedures like stemmed arthroplasty or total shoulder replacement.

Furthermore, the HemiCAP procedure disrupts the degenerative cycle of early-stage CTA, effectively addresses causes of pain, and avoids further muscle imbalance. The latter is achieved by a special deltoid muscle-splitting approach that leaves the tendon under the shoulder bone intact.

All of these advantages resulted in accelerated recovery and rehabilitation for patients.

“We are very pleased with the positive outcome of this study. Although we specialize in non-surgical stem cell interventions at RMI, sometimes, as in the case of CTA, surgical intervention is indicated. That’s why it’s important for patients to seek out an experienced orthopedic surgeon who, in addition to orthopedic expertise, is well versed on the latest advances in stem cell therapy. A surgeon needs both to know when stem cell therapy may be effective and when surgery, perhaps augmented with biologics like bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product, is a better option,” commented Dr. McKenna.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.

Southlake, Texas

76092

Tel: (817) 776-8155

Toll Free: (877) 899-7836

Fax: (817) 776-8154

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/11/prweb13068117.htm

PRESS RELEASE – UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute

MRI confirms complete healing of hamstring eight weeks after Dr. Wade McKenna administered guided injections of bone marrow aspirate concentrate (BMAC) harvested with BioMAC (patent pending) bone marrow aspiration cannula and AlphGEMS amniotic tissue product at the Riordan-McKenna Institute.

DALLAS-FORT WORTH, TEXAS (PRWEB) SEPTEMBER 03, 2015

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

Zack Bornstein with Dr. McKenna and Physicians Assistant, Troy Chandler

UCLA wide receiver and Canadian decathlon standout, Zack Bornstein suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not working so Zack decided to undergo stem cell therapy at Riordan-McKenna Institute in late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested with the BioMAC (patent pending) bone marrow aspiration cannula and *AlphGEMS amniotic tissue product.

Complete healing was confirmed by MRI 8 weeks after treatment:

1) No evidence for hamstring strain or denervation and no evidence for tendon tear.
2) No evidence for focal atrophy or hematoma.
3) No osseous abnormalities seen.

After receiving the MRI results, Zack’s father Dean said, “I am not a doctor but looks like you and your procedure has performed a medical miracle! …Thanks for all of your efforts.”

Zack is currently a red shirt freshman at UCLA. He played football at Oaks Christian High School from 2011-’14 and lettered 3 years in football and all 4 years in track. In 2013, Zack was named to the All-Marmonte 2nd team. He played in the FBU Youth All-American game in 2010. In track, he is considered to be one of the top decathletes in the country. Zack competed at the 2013 Pan American Junior Championships in Medellin, Columbia, finishing in 5th place with 7,097 points. In July of 2013, he became the Canadian Junior National Champion (6,918 pts). Zack won the silver medal at the 2013 Arcadia Invitational Decathlon, scoring 6,967 points to set a new California state record for juniors (2nd highest score in California state history). Zack is a 12-time National Champion, 44-time All-American and a member of three National Championship cross country teams.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.
BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.
Southlake, Texas
76092

Tel: (817) 776-8155
Toll Free: (877) 899-7836
Fax: (817) 776-8154

About Amniotic Therapies

Based in Dallas, Texas, Amniotic Therapies specializes in the processing and distribution of human amniotic tissue products for the biologic and regenerative medicine segments of the healthcare market. Amniotic Therapies’ mission is to provide superior human amniotic tissue products that naturally enhance the body’s healing ability, providing patients with improved healing.
Amniotic Therapies is registered with the U.S. Food and Drug Administration (FDA) and is in the process of receiving accreditation from the American Association of Tissue Banks.

http://www.amniotictherapies.com

11496 Luna Rd. Suite 800
Dallas, Texas
75235

Tel: (972) 465-0496

Case report of non-healing surgical wound treated with dehydrated human amniotic membrane

AlphaPATCH Amniotic Membrane PictureDr. Riordan and Dr. Wade McKenna recently published this case study demonstrating how amniotic tissue products promote wound healing. You can view the original article on the Journal of Translational Medicine website: Case report of non-healing surgical wound treated with dehydrated human amniotic membrane.

Authors
Neil H Riordan, Ben A George, Troy B Chandler, Randall W McKenna

Abstract

INTRODUCTION
Non-healing wounds can pose a medical challenge as in the case of vasculopathic venostasis resulting in a surgical ulcer. When traditional approaches to wound care fail, an amniotic patch (a dehydrated tissue allograft derived from human amnion) can function as a biologic scaffold to facilitate and enhance tissue regeneration and rehabilitation.

BACKGROUND
Amniotic AlphaPatches contain concentrated molecules of PGE2, WNT4, and GDF-11 which have angiogenic, trophic, and anti-inflammatory effects on tissues that may be useful in enhancing wound healing.

AIM-CASE REPORT
We present a case of a severe non-healing surgical wound in a 78-year-old male 17 days post right total knee arthroplasty. The full-thickness wound exhibited a mobile flap, measured 4 cm long × 3 cm wide, and showed undermining down to patellar tissue. We treated the wound conservatively for 6 weeks with no evidence of wound healing. Upon failure of the conservative treatment, two amniotic AlphaPatch (Amniotic Therapies, Dallas, TX, USA) were applied to the wound, and the wound healed completely in 10 weeks.

METHODS
In the OR, the wound was irrigated with three liters of double antibiotic solution under pulse lavage. Two dry amniotic AlphaPatch (4 cm × 4 cm) were placed over the wound with Acticoat applied on top.

RESULTS
At the two-week follow-up visit (following the incision and drainage of the wound dehiscence and application of the amniotic AlphaPatch), a central scab had formed centrally in the wound dehiscence area. At the four-week follow-up visit, the wound dehiscence area had completely scabbed over with no open areas left. At the eight-week follow-up visit, the scab had just fallen off, and the wound was healing well with immature skin representing the size of a penny. At the ten-week follow-up visit, the wound was completely healed.

DISCUSSION/CONCLUSION
Sterile, dehydrated amniotic tissue AlphaPatches (containing trophic factors known to enhance wound healing) have proven effective in completely healing an otherwise non-healing wound in a 78-year-old male who failed six weeks of conservative wound care treatment.

Picture of wound before treatment with AlphaPATCH amniotic membrane

Picture of wound 2 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 4 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 8 weeks after treatment with AlphaPATCH amniotic membrane

Picture of wound 8 weeks after treatment with AlphaPATCH amniotic membrane

PBS to Feature Stem Cell Therapy at Stem Cell Institute and Medistem Labs Panama in TV Special

PBS is in Panama this week filming Stem Cell Institute’s clinic, staff and patients. Yesterday, they toured Medistem Labs Panama. Here are a few pictures taken by Dr. Riordan at the lab. Watch for this special to air on PBS this fall.

PBS at Medistem Labs in Panama 4

PBS at Medistem Labs in Panama 3

PBS at Medistem Labs in Panama 2

PBS at Medistem Labs in Panama 1